In conclusion, we demonstrated that CT is a potential antitumor drug candidate in ovarian cancer therapy not only because it improves the efficacy of other chemotherapeutic drugs but more importantly because it causes the degradation of c-Myc by disrupting its stability and attenuating the FAK signaling pathway (Figure 9). This evidence concerns the gene MYC and ovarian cancer.